Exploring the scientific, political and financial headwinds impacting biopharma ambitions
With loss of exclusivity looming for some of the best-selling drugs, pharma companies are going to have to find new sources of revenue to backfill. A glance at the 2022 best selling drugs demonstrates how reliant many pharma companies are on external innovation (e.g. Humira, Comirnaty, Keytruda).
Until recently, the availability of capital facilitated the relationship between pharma and biotechs to become increasingly more symbiotic; pharma companies would provide financial resources and technical expertise while biotechs provided access to the cutting edge of science and technology. The downturn of the capital markets means industry deal making is seeing new trends. In this webinar we will take a look at what 2023 deal making looks like for both sides of pharma and biotech.
In this webinar, our panelists will answer questions such as –